Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nomlabofusp in Friedreich's Ataxia
NCT07778836Phase 3Recruiting
- Sponsor
- Larimar Therapeutics
- Start
- Oct 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 3 trial of nomlabofusp in Friedreich's ataxia (FA), sponsored by Larimar Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
nomlabofusp
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT07778836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778836.